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Abstract Venous thromboembolism (VTE) can be the first
presenting symptom in myeloproliferative neoplasms
(MPN). Studies have demonstrated a high prevalence of
the JAK2V617F mutation in patients with splanchnic vein
thrombosis. Fewer studies have been done in patients with
thrombosis outside the splanchnic area, showing a lower
prevalence although the clinical relevance of the mutation
in these patients, e.g., progression to overt MPN, remains
unknown. The objective of this study was to determine the
effect size of JAK2V617F in prospectively collected DNA
samples of patients objectively diagnosed with deep vein
thrombosis (DVT) of the leg and controls without DVT,
with follow-up on JAK2V617F-positive patients to assess
clinical relevance. Presence of JAK2V617F was determined
in DNA samples from 187 patients with DVT and 201
controls, using quantitative RT-PCR. Hematological param-
eters were also analyzed. All initially JAK2V617F-positive
patients were reassessed. Of 187 patients with DVT, 178
were analyzed for JAK2V617F, and in four (2.3%; 95% CI
0.1–4.4), JAK2V617F was present. Of 201 controls, 198
were analyzed; one was JAK2V617F positive (0.5%; 95%
CI −0.5–1.5, OR 4.5; 95% CI 0.5–40.9). None had MPN
features, nor upon reassessment after a median follow-up of
68.5 months. Four JAK2V617F-positive patients with DVT
and one control without DVT did not develop overt MPN
after a median follow-up of nearly 6 years. Thus, in patients
with non-splanchnic venous thrombosis, JAK2V617F
appears not to be clinically relevant.
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Clinical relevance
Introduction
Venous thromboembolism (VTE) is a major cause of
morbidity and mortality in Philadelphia mutation-negative
myeloproliferative neoplasms (MPN). In 12–49% of cases,
VTE can manifest years before the disease becomes clinically
apparent [1]. MPN-related VTE characteristically concerns
deep vein thrombosis (DVT), pulmonary embolism, occlu-
sion of the cerebral veins, or of the splanchnic veins, e.g.,
hepatic (Budd–Chiari syndrome), portal, splenic, or mesen-
teric veins.
In 2005, the JAK2V617F mutation was discovered that
can be found in >1% of cells in up to 97% of patients with
polycythemia vera (PV), and in 50% of patients with
essential thrombocythemia (ET), and primary myelofibrosis
(PMF) [2–4]. Analysis of JAK2V617F has been incorpo-
rated in the diagnostic criteria for MPN [5], and quantitative
analysis can also be used for monitoring of disease
response [6, 7]. JAK2V617F seems to be absent in the
healthy population [8], although some studies have found a
very low prevalence in healthy subjects [9–11], resulting in
M. N. Lauw:H. R. Koene: B. J. Biemond (*)
Department of Hematology, Academic Medical Center,
F4-224, PO Box 22660, 1100 DD Amsterdam, The Netherlands
e-mail: b.j.biemond@amc.uva.nl
E. W. N. Bus: C. H. Homburg: C. E. van der Schoot
Experimental Immunohematology, Sanquin Research at CLB,
Amsterdam, The Netherlands
A. F. Y. van Wulfften Palthe:M. Coppens:S. Middeldorp
Department of Vascular Medicine, Academic Medical Center,
Amsterdam, The Netherlands
H. R. Koene
Department of Hematology, St. Antonius Hospital,
Nieuwegein, The Netherlands
Ann Hematol (2012) 91:103–107
DOI 10.1007/s00277-011-1233-0the hypothesis that the presence of JAK2V617F in healthy
cohorts may be a first indication of an underlying MPN.
Several studies have addressed the association between
JAK2V617F and thrombosis in the absence of MPN.
JAK2V617F is strongly associated with splanchnic vein
thrombosis (SVT) and has been demonstrated in 40–60% of
patients with Budd–Chiari syndrome [12–14] and 25–50%
of patients with portal vein thrombosis [15–17]. In patients
with venous thrombosis outside the splanchnic area, the
prevalence of JAK2V617F was low (0.0–2.0%) [18–22].
However, the clinical relevance of the mutation in this
group, e.g., progression to MPN and therapeutic conse-
quences, remains unclear, as no studies to assess the risk
and timing of progression to an overt MPN have been
published so far.
Therefore, we addressed the effect and clinical
relevance of JAK2V617F in prospectively collected
DNA samples of patients diagnosed with DVT of the
leg, and in a cohort of patients in whom DVT was
objectively ruled out (controls). Hematological parame-
ters were analyzed retrospectively. Follow-up was per-
formed on all patients who harbored the JAK2V617F
mutation upon initial determination, to assess clinical
relevance based on progression of the mutated allele
burden and hematological parameters.
Materials and methods
Identification of patients and controls
DNA samples were obtained from consecutive patients of
at least 18 years old who were referred for suspicion of
acute symptomatic DVT to the Academic Medical Center
in Amsterdam, The Netherlands, between September 1999
and May 2006. The criteria for DVT were a proximal leg
vein that was not compressible on ultrasonography or
presence of an intraluminal filling defect on venography.
Proximal DVT was defined as a thrombus in the popliteal
vein, superficial femoral vein, or common femoral vein. If
compression ultrasonography showed no venous thrombo-
sis and the D-dimer plasma level was ≥0.5 mg/L,
compression ultrasonography was repeated after 7 days.
DVT was ruled out in case of a Wells score [23] ≤1i n
combination with a low D-dimer plasma level (<0.5 mg/L).
DVT was also ruled out in case of a normal venography or
negative compression ultrasound in combination with a low
D-dimer plasma level (<0.5 mg/L), and after a repeated
negative ultrasound.
We selected 187 DNA samples of consecutive patients
with objectively diagnosed DVT and 201 DNA samples of
patients without previous VTE, with a clinical suspicion of
DVT but in whom DVT was objectively excluded (con-
trols), matched individually for age (±5-year intervals) at
the time of blood sample collection. Patients with DVT
were selected irrespective of previous VTE, presence of
thrombophilia, or provoking co-morbidities. Patients with
MPN at the time of DVT diagnosis were excluded.
Hematological parameters were examined retrospectively
using patient records. DNAwas isolated from leukocytes in
peripheral blood using standard procedures and stored in
refrigerated cabinets (4°C) under anonymous codes. Blood
samples were taken after written informed consent, and the
presence of clinical risk factors for VTE was assessed using a
structured questionnaire. Collection of DNAwas approved by
the Medical Ethical Committee of the Academic Medical
Center, Amsterdam, The Netherlands, for prospective explo-
rationofunknown riskfactors ofVTE and inaccordance with
the Declaration of Helsinki.
Our follow-up strategy implied that all patients, who
harbored the JAK2V617F mutation upon initial determina-
tion, were re-evaluated in the beginning of 2009. Patients
were informed about the presence of JAK2V617F in their
DNA sample and possible consequences. Also, information
about this study was given. After informed consent, blood
samples were taken to determine hematological parameters
and to assess JAK2V617F.
Real-time quantitative TaqMan PCR
The presence of the JAK2V617F mutation was assessed
using a highly sensitive allele-specific real-time quantitative
TaqMan PCR assay, performed on an ABI 7900HT Fast
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA). After initial denaturation (20 s at 95°C) PCR
was carried out for 50 cycles at fast conditions (1 s 95°C,
20 s 60°C). TaqMan Fast Universal Master Mix (Applied
Biosystems) was used; primers (300 nM each) and probe
(200 nM) were as designed by Kröger et al. [7] and
purchased from Eurogentec (Liege, Belgium). The final
concentration is 300 nM for the primers and 200 nM for the
probe. The DNA input is 100 ng. Samples were run in
duplicate. As described by Quentmeier et al. [24], the HEL-
cell line (derived from a patient with AML M6) is positive
for the JAK2V617F mutation but has an eightfold tandem
duplication of the JAK2-gene. A tenfold dilution of this
HEL-cell line DNA is set at 100%. Serial dilution into
buffy coat-derived MNC from a pool of ten healthy donors
was used as standard curve (100%, 10%, 1%, 0.1%, and
0.01%) for quantification in cases and controls. A RQ-PCR
of albumin was performed to calibrate.
The sensitivity of our assay was 0.1%. DNA samples were
considered JAK2V617F positive if they demonstrated dupli-
cate positive signals on PCR with cycle threshold (Ct) <43. In
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Samples demonstrating duplicate positive signals with Ct ≥43
as well as samples demonstrating a single positive signal with
Ct>40 on PCR were considered negative for presence of the
JAK2V617F mutation. These criteria have been established
based on previous testing of a control cohort of healthy
volunteers (n=381). Mutated allele burdens were expressed
as the percentage of total JAK2 represented by JAK2V617F
(percent JAK2V617F) [25].
Outcome measures and statistical analysis
The primary outcomes of the study were the effect of the
JAK2V617F mutation on the risk of DVT, calculated as an
odds ratio (OR) with corresponding 95% confidence
intervals (CI), and progression to overt MPN in patients
who harbored JAK2V617F at initial assessment to assess
clinical relevance.
Results
Patient characteristics
Of 187 patients with objectively diagnosed DVT, eight
DNA samples did not yield sufficient DNA, leaving 179
(95.7%) for analysis of JAK2V617F and hematological
parameters. Of 201 controls without DVT, three samples
did not yield sufficient DNA, leaving 198 (98.5%) for
analysis. An evident MPN (PV) was retrospectively
diagnosed in one DVT-patient by examination of hemato-
logical parameters at the time of DVT diagnosis. This
patient was excluded from further analyses. Blood counts in
all remaining patients did not fulfill the diagnostic WHO
criteria for MPN [5]. Age and gender distribution did not
differ significantly between patients with and without DVT.
Of the 178 patients with DVT, 25.8% had experienced a
previous thrombotic episode. In 83 (46.6%), one or more
thrombophilic defects were detected (factor V Leiden
heterozygosity (n=27), deficient protein C or S (n=4 and
2, respectively), hyperhomocysteinemia (n=16), antiphos-
pholipids syndrome (n=9), elevated factor VIII (n=30),
prothrombin 20210A mutation (n=7)). DVT was provoked
by operation, malignancy (treatment), trauma, pregnancy,
or use of oral contraceptives in 59 cases (33.1%). In 43
cases (24.2%), no risk factors for thrombosis could be
acknowledged.
JAK2V617F mutation; initial determination
In four of 178 (2.3%; 95% CI 0.1–4.4) patients with DVT,
the JAK2V617F mutation was present using RT-PCR.
Quantitative analysis was possible in one patient
(JAK2V617F allele burden 0.87%); in the other three
cases, the mutational burden was insufficient for quantifi-
cation. In the control group without DVT, the JAK2V617F
mutation was present in one of 198 (0.5%; 95% CI −0.5–
1.5) samples, while the mutational burden was insufficient
for quantification. Hematological parameters, age, and
gender distribution did not differ significantly between
JAK2V617F-positive and negative patients. None of the
five JAK2V617F-positive patients had experienced a
previous thrombotic episode, and in four of five, DVT
occurred without known thrombophilic or provoking
factors. Presence of the JAK2V617F mutation increased
the risk for DVT 4.5-fold, although not statistically
significant (OR 4.5; 95% CI 0.5–40.9).
JAK2V617F mutation; follow-up
We reassessed all five patients who harbored JAK2V617F
for hematological parameters and JAK2V617F mutational
burden. The median follow-up was 68.5 months (range 47–
85). Upon reassessment, the JAK2V617F mutation was
present in three of five initially JAK2V617F-positive
patients. Quantification of the JAK2V617F allele burden
was only possible in the same one patient (0.95% of
leukocytes, increase of 0.08%). Hematological parameters
remained remarkably stable with regard to initial values,
and none of the patients had developed overt MPN
according to the WHO criteria (Table 1). One patient
(21484) had had a recurrent DVT during the interval.
Discussion
The JAK2V617F mutation was observed in 2.3% (95%
CI 0.1–4.4) of patients with objectively diagnosed DVT
of the leg and in one control without DVT (0.5%; 95%
CI −0.5–1.5). The low prevalence of JAK2V617F among
patients with venous thrombosis outside the splanchnic
area in the absence of MPN has been reported before
(0.0–2.0%) [18–22], but not in a distinct cohort with DVT
of the leg as in our study. Moreover, the presence of the
JAK2V617F mutation increased the risk for DVT 4.5-fold
(OR 4.5; 95% CI 0.5–40.9), although not statistically
significant. None of our JAK2V617F-positive patients
developed overt MPN after a median follow-up of
68.5 months. Therefore, we conclude that in patients with
venous thrombosis outside the splanchnic area, presence
of the JAK2V617F mutation appears not to be clinically
relevant.
To date, little is known about the clinical relevance of
JAK2V617F presence in patients without overt MPN. It is
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transformation into MPN or other hematological disorders.
Long-term follow-up in patients with SVT in the absence of
MPN is limited, but suggests subsequent development of
MPN in a considerable proportion of patients, although
certainly not in all [12, 14–17, 26]. A small follow-up study
in patients with other types of VTE could not observe MPN
transformation after a median follow-up of 40 months [19],
similar to our study.
However, it is not clear whether different therapeutic
measures should be taken for JAK2V617F positive patients
in the absence of MPN, with (or without) thrombosis. It
also remains unclear why specifically SVT is more strongly
associated with the JAK2V617F mutation in comparison
with other locations. Finally, it is not known whether early
diagnosis of MPN, based on JAK2V617F presence,
benefits the prognosis or treatment of these disorders.
Follow-up of larger JAK2V617F-positive non-MPN
cohorts, with different locations of thromboses, is necessary
to clarify these issues.
Follow-up on JAK2V617F allelic burdens has not often
been reported in VTE patients in the absence of known
MPN. A study in SVT-patients without MPN upon
diagnosis showed stability of the mutated allele proportion
in the majority of patients [14], also despite progression to
MPN. We could not detect the JAK2V617F mutation upon
reassessment after a median follow-up of 68.5 months in
two of five initially positive patients. This could be
explained by the insufficient presence of JAK2V617F in
the proportion of examined cells, making the mutation
undetectable at that instance, considering that the amount of
mutated cells was already at the detection threshold of our
sensitive assay initially. It could also be explained by
disappearance of this small clone over time. However, the
prognostic value of disappearing mutated clones is not yet
known, nor in the context of treatment with hydroxyurea
[6].
In general, prevalence assessment in all JAK2V617F
studies is much dependent on PCR assay heterogeneity [25,
27] and the clinical diagnostic positivity cutoff value. Some
studies commit to a clinical positivity cutoff of 1% of
mutated cells for diagnostic MPN implications [27, 28].
The analytical threshold of our assay was 0.1%, with DNA
samples considered JAK2V617F positive upon duplicate
positive PCR signals with Ct<43, while an allelic burden of
1% results in a Ct value of 35. Hence, samples can be
considered JAK2V617F-positive without an available
quantification of the mutated allele burden.
Highly sensitive assays like ours are necessary to
determine minimal residual disease in patients following
treatment for their MPN [6, 7]. However, it can also lead to
positive results with low allele burdens when used for
JAK2 detection in VTE patients or healthy subjects [9, 11,
27, 28]. These results should be interpreted with caution.
Although some studies suggest that JAK2V617F in these
patients may indicate an underlying MPN [9–11], the value
of its presence in these patients, especially with low
mutational levels, remains unclear. In our study, none of
the JAK2V617F-positive patients developed a clinical
diagnosis of MPN after a median follow-up of nearly
6 years. Therefore, we conclude that presence of the
JAK2V617F mutation in non-MPN patients with venous
thrombosis outside the splanchnic area appears not to be
clinically relevant.
Table 1 Characteristics and hematological parameters of JAK2V617F-positive patients at initial determination (1) and follow-up (2)
DNA sample ID
6578 (DVT) 21484 (DVT) 25287 (DVT) 33266 (DVT) 26660 (control)
121212 1 2 12
Age (years) 40 46 69 76 43 49 85 89 64 70
Sex (M/F) F M M F F
Hb (g/dL) 14.2 14.3 12.7 13.9 16.3 16.1 15.0 13.7 14.8 14.7
Ht (L/L) NA 0.42 0.39 0.41 NA 0.46 0.43 0.43 0.44 0.43
WBC (10E9/L) 9.4 9.3 9.6 4.3 5.5 6.8 7.7 10.3 6.7 7.8
Plt (10E9/L) 294 259 172 182 277 215 305 372 233 223
JAK2V617F (%) + (NQ) + (NQ) + (NQ) + (NQ) + (NQ) Neg + (0.87) + (0.95) + (NQ) Neg
Follow-up (months) 69 85 67 47 69
Status Alive Alive Alive Alive Alive
NA not available, NQ not quantifiable
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